Dr Indrani Sarkar and her team of scientists have created an enzyme that destroys the HIV virus under laboratory conditions. The Tre enzyme can detect HIV and specifically target, and unlike most medicines out there, the virus doesn't become immune to it, so the effects are long-term. According to IBN, "It's an engineered enzyme which recognises sequences in the HIV genome that is duplicated, integrated virus and by the process of recombination, it cuts out the virus from the genome."
"The only way then to cure HIV is to get rid of the virus completely and Tre, the enzyme that Indrani constructed after a year and its 126 "cycles of mutation" totally deplete HIV in the human genome in three months in laboratory conditions."
Key Themes Behind This Trend
- Antiviral Enzyme Therapies
- The development of enzymes that effectively target and destroy viruses opens up opportunities for antiviral therapies with long-term effects.
- Immunity-resistant Medicines
- The creation of medicines that are not susceptible to immune resistance presents disruptive innovation potential in the medical industry.
- Genome-targeting Therapeutics
- The ability to engineer enzymes that recognize specific sequences in the genome and remove viruses offers promising prospects for genome-targeting therapeutics.
Where This Applies
- Pharmaceuticals
- The pharmaceutical industry can explore the development and commercialization of antiviral enzymes as a new treatment approach.
- Biotechnology
- The biotechnology sector can leverage the creation of immunity-resistant medicines by utilizing advanced scientific techniques.
- Healthcare
- The healthcare industry can benefit from the potential of genome-targeting therapeutics to revolutionize the treatment of viral infections.
